Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
THRIVE: Vascular and Neurocognitive Effects of Weight Loss
NCT07592546Phase 4Recruiting
- Start
- Oct 2026
- Primary completion
- Dec 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in obesity (2 arms). Primary endpoints: Serum C-reactive Protein, Serum Pro-inflammatory Cytokines and 32 more. Started Oct 2026; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07592546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592546.